Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

doi:10.1200/JCO.2008.19.9067

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2009

Kriege Mieke, Seynaeve Caroline, Meijers-Heijboer Hanne, Collee J Margriet, Menke-Pluymers Marian B E, Bartels Carina C M, Tilanus-Linthorst Madeleine M A, Blom Jannet, Huijskens Elisabeth, Jager Agnes, van den Ouweland Ans, van Geel Bert, Hooning Maartje J, Brekelmans Cecile T M, Klijn Jan G M

Abstract excerpt

PURPOSE: Preclinical as well as a few small retrospective, neoadjuvant studies suggest that breast cancer (cells) without functional BRCA1 or BRCA2 protein have an increased sensitivity to some chemotherapeutic agents causing double-strand DNA breaks. In this study we assessed the sensitivity to standard first-line chemotherapy of metastatic BRCA1/2-associated breast cancer, compared with sporadic breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Chemotherapy, Adjuvant

Share to Disease-Free Survival

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Research Design

Source

Open in PubMed

Identifiers

PMID: 19564533
DOI: 10.1200/JCO.2008.19.9067

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.PMID 19564533Read ↗

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Systemic therapy options in BRCA mutation-associated breast cancer.Semantic proximity Read ↗

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.Semantic proximity Read ↗

[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].Semantic proximity Read ↗

[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].Semantic proximity Read ↗

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Semantic proximity Read ↗

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.Semantic proximity Read ↗

Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.Semantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.